|
Press Releases |
|
|
|
Tuesday, April 16, 2024 |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, June 12, 2023 |
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, May 22, 2023 |
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, December 19, 2022 |
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Friday, November 4, 2022 |
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Wednesday, August 24, 2022 |
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Friday, July 8, 2022 |
|
SinoMab Received the Highest Subsidy from HKSTP |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
Tuesday, June 21, 2022 |
|
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair conclude successfully
May 19, 2024 15:06 HKT/SGT
|
|
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 18:00 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
|
|
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
May 16, 2024 22:00 HKT/SGT
|
|
|
DEXIS Innovation Continues With New DEXIS Ti2 Sensor as Successor to the DEXIS Titanium Sensor, the #1 Selling Intraoral Sensor in the United States
May 16, 2024 21:30 HKT/SGT
|
|
|
Horus: Million Dollar Air-Mail NFT Drop on Base
May 16, 2024 20:11 HKT/SGT
|
|
|
HKTDC kicks off third International Healthcare Week
May 16, 2024 18:00 HKT/SGT
|
|
|
CleverTap's 2024 Market Research Report Unveils that Brands Implementing Higher AI Adoption See 4x Boost in Conversions
May 16, 2024 17:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|